Undeterred by domestic regulatory concerns, Hims & Hers is actively executing its global strategy. On December 10, the company launched its comprehensive weight-loss program in the United Kingdom, ...

We tested adult diapers in our labs and got feedback from regular users to find the very best adult diapers and incontinence ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

At an FDA discussion of testosterone replacement therapy, a top official called for special health centers to address a ...

HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.

Delving into the details, we found 53% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $373,316, and 7 were calls, valued ...

In a strategic pivot, the company has launched its weight-loss program in the United Kingdom. There, Hims & Hers is offering legitimate, branded medications—Novo Nordisk's Wegovy and Eli Lilly's ...

Women are healthcare’s power users yet face diagnostic delays, higher dismissal rates, and AI bias. New innovators aim to ...

According to researchers, medical training has reached a stage where students know more, but understand less. Although there ...

Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could ...

Tempus AI's shift toward scalable revenues, high-margin data services and broader AI capabilities defines a pivotal moment for TEM investors.